Immunotoxicity Assessment in Drug Development

Includes a Live Web Event on 08/05/2026 at 11:30 AM (EDT)

The last several years have witnessed many advancements within the field of immunotoxicology. These advancements include new therapeutic options to treat inflammatory and autoimmune diseases, identification of new immune targets, mechanisms, and potential safety concerns, and the development of new immunotoxicity assays. The types of immune effects encountered can vary dramatically and present unique challenges during drug development. This session will address the various types of immunotoxicities, and the nonclinical assays and strategies used to address them. An overview of the guidance documents pertinent to nonclinical immunotoxicity assessment will also be included.

Key:

Complete
Failed
Available
Locked
Upcoming Webinar
08/05/2026 at 11:30 AM (EDT)  |  90 minutes
08/05/2026 at 11:30 AM (EDT)  |  90 minutes
You must register to access.
David McMillan, PhD, DABT

David McMillan, PhD, DABT

Master Toxicologist

Division of Pharmacology/Toxicology for Infectious Diseases, US FDA

Dr. David McMillan is a board-certified toxicologist in the Division of Pharmacology/Toxicology for Infectious Diseases at the FDA. Prior to the FDA, Dr. McMillan received his PhD in Toxicology from the University of Rochester in 2013 and completed a postdoctoral fellowship at the University of Vermont in 2015. His expertise lies primarily in immunology and immunotoxicology. Within ACT, Dr. McMillan has served on the Early Career Professional Subcommittee and the Education Committee and is a current member of the Membership Committee. He has also chaired multiple sessions and given multiple presentations within ACT, including the “Hematopoietic and Immune Systems Toxicology” presentation for ACT’s Advanced Comprehensive Toxicology course.